Combined with the finding that PCK2 inhibits the progression of RCC and increases the sensitivity to sunitinib, we can use specific drugs to reduce the methylation level of the PCK2 promoter region, thereby restoring epigenetically silenced PCK2 expression to inhibit RCC progression. Here, PCK2 is linked to renal cell carcinoma.